| 1. |
Schmitz J, Owyang A, Oldham E, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-l receptor-related protein ST2 and induces T helper type 2-associated cytokines[J]. Immunity, 2005, 23(5): 479-490．.
|
| 2. |
Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1receptor[J]. FEBS Lett, 1989, 258(2): 301-304．.
|
| 3. |
Chackerian AA, Oldham ER, Murphy EE, et al. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex[J].Immunol, 2007, 179 (4): 2551-2555.
|
| 4. |
Dinarello CA. An IL-l family member requires caspase-1 processing and signals through the ST2 receptor[J].Immunity, 2005, 23(5): 46l-462.
|
| 5. |
Ali S, Huber M, Kollewe C, Bischoff SC, et al. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells[J]. Proc Natl Acad Sci USA, 2007, 104(47): 18660-18665.
|
| 6. |
Rank MA, Kobayashi T, Kozaki H, et al. IL-33-activated dendritic cells induce an atypical TH2-type response[J]. J Allergy Clin Immunol, 2009, 123(5): 1047-1054.
|
| 7. |
Miller AM, Xu D, Asquith DL, et al. IL-33 reduces the development of atherosclerosis[J]. J Exp Med, 2008, 205(2): 339-346.
|
| 8. |
Komai-Koma M, Gilchrist DS, McKenzie AN, et al. IL-33 activates B1 cells and exacerbates contact sensitivity[J]. J Immunol, 2011, 186(4): 2584-2591.
|
| 9. |
Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4[J]. J Immunol, 2008, 181(7): 4780-4790.
|
| 10. |
Xu D, Jiang HR, Kewin P, et a1. IL-33 exacerbates antigen-induced arthritis by activating mast cells[J]. Proc Natl Acad Sci USA, 2008, 105(31): l0913-109l8．.
|
| 11. |
陈立辉, 张源潮, 孟红艳.检测早期类风湿关节炎(RA)患者血清中IL-33水平的临床意义[J].中国医药指南, 2012, 15(10): 424-425.
|
| 12. |
刘玥,周迎春,黄钟.类风湿性关节炎患者IL-33水平变化与疾病严重程度的关系[J].医学检验与临床, 2012, 23(3): 54-56.
|
| 13. |
黄鹤卿, 穆荣, 刘霞, 等．白细胞介素-33的测定及其与早期类风湿关节炎相关性的研究[J]. 中华风湿病学杂志, 2010, 14(7): 446-448.
|
| 14. |
施巍宇, 杨再兴. 血清IL-33与系统性红斑狼疮的关系研究[J]. 现代检验医学杂志, 2010, 25(5): 5-7.
|
| 15. |
Mok MY, Huang FP, Lp WK, et al. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus[J]. Rheumatology (Oxford), 2010, 49(3): 520-527.
|
| 16. |
Manetti M, Ibba-Manneschi L, Liakouli V, et al. The IL1-like cytokine IL 33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis[J]. Ann Rheum Dis, 2010, 69(3): 598-605.
|
| 17. |
Yanaba K, Yoshizaki A, Asano Y, et al. Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis[J]. Clin Rheumatol, 2011, 30(6): 825-830.
|
| 18. |
Manetti M, Guiducci S, Ceccarelli C, et al. Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement[J]. Ann Rheum Dis, 2011, 70(10): 1876-1878.
|
| 19. |
Rankin AL, Mumm JB, Murphy E, et al. IL-33 induces IL-13-dependent cutaneous fibrosis[J]. J Immunol, 2010, 184(3): 1526-1535.
|
| 20. |
Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation[J]. J Clin Invest, 2006, 116(5): 1218-1222.
|
| 21. |
IHan GW, Zeng LW, Liang CX, et al. Serum levels of IL-33 is increased in patients with ankylosing spondylitis[J]. Clin Rheumatol, 2011, 30(12): 1583-1588.
|
| 22. |
ITalabot-Ayer D, McKee T, Gindre P, et al. Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis[J]. Joint Bone Spine, 2012, 79(1): 32-37.
|
1/5
微信公众号